Ekblad E, Jongsma H, Brabet P, Bockaert J, Sundler F
Department of Physiological Sciences, Lund University, Lund, Sweden.
Ann N Y Acad Sci. 2000;921:137-47. doi: 10.1111/j.1749-6632.2000.tb06960.x.
The receptors for VIP and PACAP were characterized in vitro on rat ileal and colonic longitudinal smooth muscle with adherent myenteric ganglia. Colon strips from PAC1 receptor knockout and wildtype mice were also examined. VIP, PACAP-38 and PACAP-27 all caused concentration dependent relaxations. In rat ileum three different types of smooth muscle VIP/PACAP receptors were defined: (1) a PACAP-27 preferring receptor coupled to apamin sensitive Ca(2+)-dependent K+ channels, (2) a PAC1 receptor activated by both PACAP-27 and PACAP-38, and (3) a VIP specific receptor regulated by NPY. The receptors identified in rat colon were: (1) a PAC1 receptor localized on NO synthesizing neurones. Activation leads to increased NO production. (2) A smooth muscle PAC1 receptor. The responses elicited by both receptors were abolished by apamin. (3) A smooth muscle VIP specific receptor. PAC1 receptor knockout mice did not respond to PACAP-27 or PACAP-38, whereas VIP induced a relaxatory response indicating the presence of a VIP specific receptor. In wildtype mice all three peptides elicited relaxatory responses. Pharmacological characterization of intestinal VIP/PACAP receptors indicates the existence of receptors, such as a PACAP-27 preferring receptor and a VIP specific receptor, distinct from those that have been cloned (VPAC1, VPAC2, and PAC1).
利用附着有肌间神经节的大鼠回肠和结肠纵行平滑肌,在体外对血管活性肠肽(VIP)和垂体腺苷酸环化酶激活肽(PACAP)的受体进行了特性研究。还检测了来自PAC1受体基因敲除小鼠和野生型小鼠的结肠条。VIP、PACAP - 38和PACAP - 27均引起浓度依赖性舒张。在大鼠回肠中确定了三种不同类型的平滑肌VIP/PACAP受体:(1)一种优先结合PACAP - 27的受体,与蜂毒明肽敏感的钙依赖性钾通道偶联;(2)一种由PACAP - 27和PACAP - 38共同激活的PAC1受体;(3)一种受神经肽Y(NPY)调节的VIP特异性受体。在大鼠结肠中鉴定出的受体有:(1)一种位于一氧化氮合成神经元上的PAC1受体。激活该受体可导致一氧化氮生成增加。(2)一种平滑肌PAC1受体。两种受体引发的反应均被蜂毒明肽消除。(3)一种平滑肌VIP特异性受体。PAC1受体基因敲除小鼠对PACAP - 27或PACAP - 38无反应,而VIP可诱导舒张反应,表明存在VIP特异性受体。在野生型小鼠中,所有三种肽均引发舒张反应。肠道VIP/PACAP受体的药理学特性表明,存在一些与已克隆的受体(VPAC1、VPAC2和PAC1)不同的受体,如优先结合PACAP - 27的受体和VIP特异性受体。